Who Owns Aktis Oncology Stock?
NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 77.44%
- Held by insiders
- 14.01%
- Institutional holders
- 171
- Institutions 77.4%
- Insiders 14.0%
- Public and other 8.6%
Who owns Aktis Oncology stock?
Institutional investors own about 77.4% of Aktis Oncology's shares, spread across 171 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 14.01% of AKTS.
The largest institutional holders are MPM Bioimpact LLC (8.97%), EcoR1 Capital, LLC (8.95%) and Blue Owl Capital Holdings LP (6.20%). Together, the top 10 institutions control 47.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their AKTS positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of AKTS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| MPM Bioimpact LLC | 4.84M | 8.97% | 0.0% |
| EcoR1 Capital, LLC | 4.82M | 8.95% | 0.0% |
| Blue Owl Capital Holdings LP | 3.34M | 6.20% | +8.9% |
| T. Rowe Price Investment Management, Inc. | 3.33M | 6.18% | +62.5% |
| Blackrock Inc. | 2.78M | 5.16% | +22.1% |
| RTW Investments LP | 1.59M | 2.95% | 0.0% |
| Wellington Management Group, LLP | 1.47M | 2.73% | -25.1% |
| Price (T.Rowe) Associates Inc | 1.18M | 2.20% | +55.2% |
| Vanguard Capital Management LLC | 1.18M | 2.19% | +44.5% |
| Eventide Asset Management LLC | 1.06M | 1.97% | +110.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of AKTS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.46M | 2.71% |
| iShares Trust-iShares Russell 2000 ETF | 730.98K | 1.36% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 676.58K | 1.25% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 585.13K | 1.09% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 509.92K | 0.95% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 507.00K | 0.94% |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 358.95K | 0.67% |
| T. Rowe Price Health Sciences Fund, Inc. | 333.75K | 0.62% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 322.17K | 0.60% |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 266.50K | 0.49% |
Frequently asked questions
Who is the largest shareholder of Aktis Oncology?
MPM Bioimpact LLC is the largest institutional shareholder of AKTS, owning 8.97% of shares outstanding (4.84M shares) as of its latest 13F filing.
What percentage of Aktis Oncology is owned by institutions?
Institutions own about 77.4% of AKTS shares and 90.0% of the public float.
How much of Aktis Oncology do insiders own?
Insiders, such as officers and directors, own about 14.01% of AKTS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.